{"id":53363,"date":"2023-09-20T09:45:20","date_gmt":"2023-09-20T09:45:20","guid":{"rendered":"https:\/\/medsname.com\/jakavi\/"},"modified":"2026-04-30T16:30:28","modified_gmt":"2026-04-30T16:30:28","slug":"jakavi","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/jakavi\/","title":{"rendered":"Jakavi"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin-top:0;\">Rychl\u00e1 odpov\u011b\u010f<\/h3>\n<p style=\"margin-bottom:0;\"><strong>Jakavi<\/strong> \u2014 Ruxolitinib 5\/20 mg (Novartis). Inhibitor JAK1\/JAK2 pro myelofibr\u00f3zu, polycyt\u00e9mii vera (rezistentn\u00ed\/nesn\u00e1\u0161ej\u00edc\u00ed hydroxyureu), reakci \u0161t\u011bpu proti hostiteli.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f7f7f7;border-left:4px solid #2c7cb0;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0 0 6px 0;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong><\/p>\n<ul style=\"margin:6px 0 0 22px;padding:0;list-style:disc;\">\n<li>v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/li>\n<li>Diskr\u00e9tn\u00ed balen\u00ed v oby\u010dejn\u00e9 ob\u00e1lce<\/li>\n<li>Dod\u00e1n\u00ed po cel\u00e9m sv\u011bt\u011b<\/li>\n<li>Hodnoceno v\u00edce ne\u017e 1 400 z\u00e1kazn\u00edky (<a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">\u010d\u00edst recenze<\/a>)<\/li>\n<\/ul>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"background:#eef7ee;border-left:4px solid #4caf50;padding:10px 14px;margin:14px 0;border-radius:3px;\">\ud83d\udce6 <strong>Z\u00e1ruka op\u011btovn\u00e9ho zasl\u00e1n\u00ed:<\/strong> pokud va\u0161e objedn\u00e1vka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f od odesl\u00e1n\u00ed, za\u0161leme ji znovu bez dal\u0161\u00edch n\u00e1klad\u016f. <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\">P\u0159e\u010d\u00edst podm\u00ednky<\/a>.<\/p>\n<h3>Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Jakavi je expedov\u00e1n od v\u00fdrobce certifikovan\u00e9ho WHO-GMP v neutr\u00e1ln\u00edm balen\u00ed, fakturov\u00e1no p\u0159es regulovan\u00e9ho platebn\u00edho procesora (na v\u00fdpisu z karty se zobraz\u00ed regulovan\u00fd platebn\u00ed procesor \u2014 nikdy MedsBase nebo n\u00e1zev l\u00e9ku). Ka\u017ed\u00e1 objedn\u00e1vka je kryta na\u0161\u00ed 20-pracovn\u00ed denn\u00ed z\u00e1rukou na p\u0159eposl\u00e1n\u00ed.<\/p>\n<div class=\"medsbase-specialist-strip\" style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0;\"><strong>\u26a0\ufe0f Specializovan\u00e1 onkologick\u00e1 l\u00e9\u010dba pod dohledem l\u00e9ka\u0159e<\/strong> \u2014 tento l\u00e9k je zahajov\u00e1n, monitorov\u00e1n a ukon\u010dov\u00e1n onkologem nebo hematologem. D\u00e1vkov\u00e1n\u00ed z\u00e1vis\u00ed na typu n\u00e1doru, stadiu, t\u011blesn\u00e9m povrchu, funkci org\u00e1n\u016f a sou\u010dasn\u00e9 terapii. Samol\u00e9\u010dba nen\u00ed vhodn\u00e1; n\u00ed\u017ee uveden\u00e9 informace jsou vzd\u011bl\u00e1vac\u00ed a podporuj\u00ed informovan\u00e9 rozhovory s va\u0161\u00edm specialistou.<\/p>\n<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Principy t\u0159\u00eddy TKI<\/strong><br \/>Inhibitory tyrozinkin\u00e1z jsou peror\u00e1ln\u00ed c\u00edlen\u00e9 terapie. Vy\u017eaduj\u00ed specializovan\u00e9 zah\u00e1jen\u00ed, pr\u016fb\u011b\u017en\u00e9 terapeutick\u00e9 monitorov\u00e1n\u00ed hladin l\u00e9\u010diva (kde je dostupn\u00e9) a zvl\u00e1d\u00e1n\u00ed t\u0159\u00eddn\u011b specifick\u00fdch toxicit. Dodr\u017eov\u00e1n\u00ed l\u00e9\u010dby je kl\u00ed\u010dov\u00e9 \u2013 vynechan\u00e9 d\u00e1vky zvy\u0161uj\u00ed riziko selh\u00e1n\u00ed l\u00e9\u010dby. V\u011bt\u0161ina TKI jsou substr\u00e1ty CYP3A4 s v\u00fdznamn\u00fdmi l\u00e9kov\u00fdmi interakcemi.<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Cytopenie + infekce + abstinen\u010dn\u00ed syndrom<\/strong><br \/>D\u00e1vkov\u011b z\u00e1visl\u00e1 an\u00e9mie, trombocytopenie, neutropenie. Zv\u00fd\u0161en\u00e9 riziko oportunn\u00edch infekc\u00ed (PCP, herpes, reaktivace TBC, reaktivace hepatitidy B). N\u00e1hl\u00e9 vysazen\u00ed m\u016f\u017ee zp\u016fsobit rebound p\u0159\u00edznaky \u2013 sni\u017eujte d\u00e1vku postupn\u011b, nikoli n\u00e1hle. Riziko sekund\u00e1rn\u00edho ko\u017en\u00edho karcinomu.<\/div>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3>Co je TKI?<\/h3>\n<p>Inhibitory tyrozinkin\u00e1z blokuj\u00ed specifick\u00e9 sign\u00e1ln\u00ed dr\u00e1hy, kter\u00e9 podporuj\u00ed r\u016fst n\u00e1dorov\u00fdch bun\u011bk. Ka\u017ed\u00fd TKI je selektivn\u00ed pro r\u016fzn\u00e9 c\u00edle (EGFR pro gefitinib\/erlotinib; multikin\u00e1za pro sorafenib\/sunitinib; BCR-ABL pro nilotinib\/imatinib; BTK pro ibrutinib; JAK pro ruxolitinib; CDK4\/6 pro palbociclib).<\/p>\n<h3>Vedlej\u0161\u00ed \u00fa\u010dinky?<\/h3>\n<p>Charakteristick\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky: vyr\u00e1\u017eka (\u010dasto koreluje s odpov\u011bd\u00ed u inhibitor\u016f EGFR), pr\u016fjem, \u00fanava, ko\u017en\u00ed reakce na dlan\u00edch a plosk\u00e1ch, hypertenze (multikin\u00e1zov\u00e9 inhibitory), hepatotoxicita, prodlou\u017een\u00ed QT intervalu. Ka\u017ed\u00fd TKI m\u00e1 specifick\u00fd profil.<\/p>\n<h3>Interakce l\u00e9k\u016f?<\/h3>\n<p>V\u011bt\u0161ina TKI jsou substr\u00e1ty CYP3A4. Siln\u00e9 inhibitory (azoly, makrolidy, ritonavir, grapefruit) zvy\u0161uj\u00ed hladiny a toxicitu; siln\u00e9 induktory (rifampicin, fenytoin, karbamazepin, t\u0159ezalka te\u010dkovan\u00e1) sni\u017euj\u00ed hladiny a zvy\u0161uj\u00ed riziko selh\u00e1n\u00ed l\u00e9\u010dby.<\/p>\n<h3>U\u017e\u00edvat s j\u00eddlem?<\/h3>\n<p>N\u011bkter\u00e9 TKI (lapatinib, erlotinib) se u\u017e\u00edvaj\u00ed nala\u010dno (potrava variabiln\u011b zvy\u0161uje biologickou dostupnost). Jin\u00e9 (gefitinib, sorafenib) lze u\u017e\u00edvat s j\u00eddlem nebo bez. Konkr\u00e9tn\u00ed instrukce z\u00e1vis\u00ed na molekule \u2013 potvr\u010fte s p\u0159edepisuj\u00edc\u00edm onkologem.<\/p>\n<h3>Jak prob\u00edh\u00e1 monitorov\u00e1n\u00ed odpov\u011bdi?<\/h3>\n<p>Zobrazovac\u00ed metody (CT\/MRI\/PET) ka\u017ed\u00e9 2-3 m\u011bs\u00edce na za\u010d\u00e1tku; n\u00e1dorov\u00e9 markery, pokud jsou relevantn\u00ed. L\u00e9\u010dba pokra\u010duje, dokud je p\u0159\u00ednos; zm\u011bna p\u0159i progresi nebo nep\u0159ijateln\u00e9 toxicit\u011b.<\/p>\n<h3>Rezistence?<\/h3>\n<p>Rezistence na TKI se vyv\u00edj\u00ed v \u010dase (obvykle 9-18 m\u011bs\u00edc\u016f u solidn\u00edch n\u00e1dor\u016f). Mechanismy: mutace c\u00edle (T790M pro EGFR, T315I pro BCR-ABL), aktivace alternativn\u00edch drah, nadm\u011brn\u00e1 exprese c\u00edle. TKI nov\u00e9 generace (osimertinib, ponatinib) p\u0159ekon\u00e1vaj\u00ed specifick\u00e9 rezistentn\u00ed mutace.<\/p>\n<h3>Co kdy\u017e vynech\u00e1m d\u00e1vku?<\/h3>\n<p>Pokud si vzpomenete ve stejn\u00fd den a je to v\u00edce ne\u017e 6 hodin do dal\u0161\u00ed d\u00e1vky, u\u017eijte d\u00e1vku. Jinak vynechejte \u2013 neduplikujte d\u00e1vku. Konkr\u00e9tn\u00ed instrukce se li\u0161\u00ed podle l\u00e9ku; potvr\u010fte s onkologick\u00fdm t\u00fdmem.<\/p>\n<h3>T\u011bhotenstv\u00ed?<\/h3>\n<p>V\u0161echny TKI jsou teratogenn\u00ed \u2013 \u00fa\u010dinn\u00e1 antikoncepce b\u011bhem l\u00e9\u010dby a alespo\u0148 4-6 m\u011bs\u00edc\u016f po n\u00ed u obou partner\u016f.<\/p>\n<h3>Kardiologick\u00e9 monitorov\u00e1n\u00ed?<\/h3>\n<p>Multikin\u00e1zov\u00e9 TKI (sorafenib, sunitinib): monitorov\u00e1n\u00ed TK, EKG (QT interval), echokardiografie ve vybran\u00fdch p\u0159\u00edpadech. BCR-ABL TKI (nilotinib): povinn\u00e9 EKG na za\u010d\u00e1tku a v pr\u016fb\u011bhu \u2013 prodlou\u017een\u00ed QT intervalu.<\/p>\n<h3>N\u00e1kladov\u00e1 efektivita?<\/h3>\n<p>Generick\u00e9 inhibitory tyrozinkin\u00e1z (TKI) se v Indii a dal\u0161\u00edch jurisdikc\u00edch hojn\u011b vyr\u00e1b\u011bj\u00ed na z\u00e1klad\u011b dobrovoln\u00fdch licenc\u00ed. Ceny indick\u00fdch generik jsou v\u00fdrazn\u011b ni\u017e\u0161\u00ed ne\u017e u origin\u00e1ln\u00edch p\u0159\u00edpravk\u016f. Kvalita a bioekvivalence jsou dob\u0159e zdokumentov\u00e1ny.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Dal\u0161\u00ed l\u00e9ky na rakovinu<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/xeloda\/\">Xeloda<\/a> \u2014 kapecitabin 500 mg \u2014 peror\u00e1ln\u00ed profarmakon 5-FU pro karcinom prsu\/kolorekta\/\u017ealudku<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/altraz\/\">Altraz<\/a> \u2014 anastrozol 1 mg \u2014 inhibitor aromat\u00e1zy pro postmenopauz\u00e1ln\u00ed karcinom prsu<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/xbira\/\">Xbira<\/a> \u2014 abirateron 250 mg \u2014 inhibitor CYP17 pro metastatick\u00fd karcinom prostaty<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/zoldria\/\">Zoldria<\/a> \u2014 kyselina zoledronov\u00e1 IV \u2014 pro kostn\u00ed metast\u00e1zy a hyperkalc\u00e9mii<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/actorise\/\">Actorise<\/a> \u2014 darbepoetin alfa \u2014 pro an\u00e9mii vyvolanou chemoterapi\u00ed<\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:18px 0;border-radius:3px;font-size:.95em;\"><strong>Zdravotn\u00ed upozorn\u011bn\u00ed:<\/strong> L\u00e9\u010dba rakoviny je vysoce individualizovan\u00e1. Konkr\u00e9tn\u00ed l\u00e9k, d\u00e1vkov\u00e1n\u00ed, re\u017eim, monitorov\u00e1n\u00ed a podp\u016frn\u00e1 p\u00e9\u010de mus\u00ed b\u00fdt stanoveny kvalifikovan\u00fdm onkologem nebo hematologem na z\u00e1klad\u011b biologie n\u00e1doru, stadia onemocn\u011bn\u00ed, p\u0159idru\u017een\u00fdch chorob a c\u00edl\u016f l\u00e9\u010dby. Tyto informace jsou vzd\u011bl\u00e1vac\u00edho charakteru; nenahrazuj\u00ed odborn\u00e9 l\u00e9ka\u0159sk\u00e9 poradenstv\u00ed.<\/div>","protected":false},"excerpt":{"rendered":"<p>Jakavi (Ruxolitinib 5\/20 mg) \u2014 inhibitor JAK1\/JAK2 od Novartis pro myelofibr\u00f3zu, polycyt\u00e9mii vera (rezistentn\u00ed\/nesn\u00e1\u0161ej\u00edc\u00ed hydroxyureu), reakci \u0161t\u011bpu proti hostiteli.<\/p>","protected":false},"featured_media":53364,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53363","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"outofstock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/53363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=53363"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/53364"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=53363"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=53363"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=53363"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=53363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}